FibroGen Appoints John Hunter, Ph.D. as Chief Scientific Officer

SAN FRANCISCO, July 12, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced the appointment of John Hunter, Ph.D., to the position of Chief Scientific Officer, where he will lead FibroGen’s research efforts, leveraging more than 20 years of global biopharmaceutical leadership and experience.

Click to view original post